Life Sciences

  • May 27, 2016

    Neovasc Ducks Mass. Law Claim In Medical Device IP Suit

    A Canadian biotech firm recently hit with a $70 million verdict in a patent and trade secrets lawsuit won a reprieve on one of the suit’s two pending claims Friday, when a federal judge ruled it wasn’t liable for unfair business practices under Massachusetts law because most of the harm occurred in Canada.

  • May 27, 2016

    5 Signs You'll Never Excel In BigLaw

    Modern priorities like finding a work-life balance might be a newer factor discouraging careers in BigLaw, but the industry has always been especially tough on individuals who work better on their own, as well as those who struggle to market themselves, experts say. Here are five dead giveaways that an attorney won’t succeed in BigLaw.

  • May 27, 2016

    Gibson Dunn DQ Shows Danger Of Handling Privileged Emails

    A California state judge recently disqualified Gibson Dunn as defense counsel for McDermott Will & Emery LLP in a malpractice matter, a finding that legal experts say stands as a warning in matters where third parties end up with privileged emails in their hands.

  • May 27, 2016

    Chelsea Therapeutics Settles Investor Class Action For $5.5M

    Chelsea Therapeutics International Inc. has agreed to pay $5.5 million in cash to settle an investor’s putative securities class action stemming from alleged misstatements about its blood pressure drug Northera, the investor told a North Carolina federal court Friday.

  • May 27, 2016

    Merrill Lynch, Citi Hit In Class Action Over Cancer Co. IPO

    Merrill Lynch, Citigroup and others involved with a West Coast cancer-treatment company's $240 million initial public offering last year allegedly overstated its financial prospects, which led to a massive drop in its stock price, investors said in a putative class action filed on Wednesday in California state court.

  • May 27, 2016

    Lipitor Retailers Push 3rd Circ. To Revive Pay-For-Delay Claims

    Walgreen, Rite Aid and other retailers urged the Third Circuit Friday to revive claims that Pfizer paid Ranbaxy to postpone releasing a generic of the cholesterol drug Lipitor and said Pfizer’s argument that the case should go to the Federal Circuit if the district court’s dismissal is overturned is incorrect.

  • May 27, 2016

    Abbott Pushes To Exclude Depakote Testimony On Eve Of Trial

    Abbott Laboratories filed a motion Thursday seeking to exclude expert evidence from a mid-June bellwether trial over Depakote-related birth defects, saying a doctor's opinions that exposure to the anti-convulsant drug caused a child's cognitive problems and behavioral problems are not admissible.

  • May 27, 2016

    Medical Device Co. Says IP Suit Triggers Defamation Policy

    Hernia mesh manufacturer Tela Bio Inc. told a New Jersey federal judge on Thursday that its insurance company is required to cover its defense costs in a trade secret infringement suit, saying allegations rise to the level of defamation covered under its policy.

  • May 27, 2016

    FDA Delays Approval Of AstraZeneca Unit's Potassium Drug

    The U.S. Food and Drug Administration has initially rejected a drug to treat high potassium levels made by a newly acquired AstraZeneca unit, citing manufacturing issues, the London-based drugmaker said Friday.

  • May 26, 2016

    GOP Reps Chide HHS On Off-Label Marketing, Urge Changes

    High-ranking Republican lawmakers on Thursday accused the U.S. Department of Health and Human Services of hamstringing new guidance on acceptable off-label promotion for prescription drugs and medical devices, and they floated legislation to loosen limits on promotion.

  • May 26, 2016

    Bayer Tops Pharma Reputation Report, Pfizer At Bottom

    Bayer AG has the best reputation among 14 large drugmakers, and Pfizer Inc. is held in the lowest regard, according to a global survey of the general public released on Wednesday.

  • May 26, 2016

    Another Customer Hits Theranos With Blood Test Rip-Off Suit

    Theranos Inc. was hit with a second proposed consumer class action in two days Thursday when a customer accused the company of defrauding consumers by claiming that its blood tests were accurate, in a suit filed by Hagens Berman Sobol Shapiro LLP in California federal court.

  • May 26, 2016

    JPML Skeptical Of Consolidating Heart Med Suits

    A five-judge panel of the Judicial Panel for Multidistrict Litigation on Thursday appeared unconvinced that nine lawsuits asserting a host of injuries by patients who took some version of the heart medication amiodarone should be consolidated in Texas federal court, repeatedly asking plaintiffs’ attorneys how the cases were related.

  • May 26, 2016

    J&J Seeks To Pause Hip Implant Trials After $498M Verdict

    Johnson & Johnson has asked a Texas federal judge to put upcoming bellwether trials on ice in the multidistrict litigation over allegedly defective Pinnacle hip prosthetics manufactured by its DePuy Orthopaedics Inc. unit, as it intends to appeal a whopping $497.6 million verdict.

  • May 26, 2016

    Quinn Emanuel's New Zurich Office To Focus On Disputes

    Quinn Emanuel Urquhart & Sullivan said Wednesday it has opened an office in Zurich with a team of lawyers experienced in transnational litigation and international arbitration, complex financial disputes, and dispute resolution in international sports, pharmaceuticals and commodities trading.

  • May 26, 2016

    KaloBios Seeks To Award Board Members For Saving Business

    KaloBios Pharmaceuticals Inc. is looking to award equity bonuses to board members the company brought on after the drugmaker filed for bankruptcy late last year following the arrest of former CEO Martin Shkreli, saying in court papers filed Wednesday in Delaware that their leadership stabilized the business under challenging circumstances.

  • May 26, 2016

    FDA OKs Buprenorphine Implant To Treat Opioid Addiction

    The U.S. Food and Drug Administration on Thursday approved Probuphine, an implant that provides buprenorphine to treat opioid addiction in six-month stretches, as an alternative to the now-available daily pill or dissolvable film.

  • May 26, 2016

    Pols Wants Answers On Colombian Drug Licensing Policy

    Fifteen Democratic lawmakers on Wednesday pressed the Obama administration to explain recent reports that it discouraged the Colombian government from issuing a license that would have invalidated a Novartis cancer drug patent to make way for a cheaper generic.

  • May 26, 2016

    FDA Inaction On Shellfish Petition Dangerous, Suit Alleges

    The U.S. Food and Drug Administration is taking an illegally long time to respond to a citizen petition to set standards that would cut down on deadly bacterial contamination in shellfish, according to a suit filed Wednesday in Washington, D.C., federal court by a consumer advocacy group.

  • May 25, 2016

    Genetically Modifying Mosquitoes Could Stem Spread Of Zika

    Travel advisories, private homeowners protecting their properties, and genetic modification could help combat the spread of the Zika virus, witnesses told a U.S. House committee on Wednesday, during a hearing examining the science of the disease and the mosquito that transmits it.

Expert Analysis

  • FDA And Digital Health: Time For A Cultural Exchange

    Albert F. Cacozza

    Health care is increasingly becoming the target of tech industry disruptors, but the amount of regulation involved can lead to an unproductive atmosphere full of frustration. A cultural exchange would facilitate a conversation between the regulators and the tech industry so that the two sides can become familiar with each other and work toward a meeting of the minds, say Albert Cacozza and Abram Barth at Ropes & Gray LLP.

  • Behind The Curtain: Technical Advisers In Complex Cases

    Christopher S. Finnerty

    During complex litigation, litigants often retain consulting experts to help them understand any intricate aspects of social and natural sciences present in a case, but the federal rules provide no such mechanism for the presiding judge. That is where technical advisers come in, say attorneys at K&L Gates LLP.

  • Takeaways From Chelsea Therapeutics Post-Closing Action

    Philip Richter

    The Delaware Chancery Court’s decision in Chelsea Therapeutics Stockholder Litigation highlights that, as reflected in the trend of Delaware decisions over the past couple of years, there is only a narrow path to success in establishing liability of independent and disinterested directors in a post-closing damages action, say attorneys with Fried Frank Harris Shriver & Jacobson LLP.

  • Driven By Abstraction: Flaws In USPTO, Court 101 Analyses

    Mac Waldbaum

    The Federal Circuit's recent comments in Enfish v. Microsoft are not helpful to understanding the meaning of an "abstract idea.” The U.S. Patent and Trademark Office and the courts are dismantling some of our country’s most important advances and innovations by manipulating basic definitions of rights given inventors under Section 101, says Mac Waldbaum of Eaton & Van Winkle LLP.

  • How To Prepare Your Employees For Litigation Discovery

    Charles N. McGee III

    The discovery process can be stressful and nerve-wracking for a company’s employees. Their reactions can vary tremendously and the effects are often overlooked by general counsels. Keeping your employees informed and educated prior to and during a collection or preservation hold can help to minimize disruption, maintain productivity and help discovery budgets stay in line with projections, say attorneys at Murphy & McGonigle PC.

  • 5 Tips For Negotiating And Drafting Joint E-Discovery Plans

    Anthony J. Rospert

    Courts often require parties to develop a joint e-discovery plan. But even when they are not court-imposed, parties should consider using joint e-discovery plans to promote transparency and streamline the discovery process, say Anthony Rospert and Jake Evans of Thompson Hine LLP.

  • An FCA Update As We Await High Court's Escobar Decision

    Brad Robertson

    The federal False Claims Act may soon be reshaped. With a case pending before the U.S. Supreme Court on the controversial theory of implied false certification, a pair of interesting cases in the Second Circuit and a recent House Judiciary Subcommittee raising issues of FCA reform, the law may face changes in text or interpretation, say attorneys with Bradley Arant Boult Cummings LLP.

  • Calif. Asbestos Case Opens Door For Shaky Expert Opinions

    Thomas A. Manakides

    While the California Court of Appeal's holding in Davis v. Honeywell can and should be limited to the specific facts and expert testimony in that case, the decision serves as a warning that courts may not always vigorously enforce their responsibility to screen expert opinions, which could open the door for plaintiffs in asbestos cases to depend on testimony that may not be entirely reliable, say attorneys at Gibson Dunn & Crutcher LLP.

  • Panama Papers: Reminders About Law Firm Cybersecurity

    Sean Doherty

    Nowhere is the attractiveness of law firms as cybercrime targets more evident than the recent Mossack Fonseca hack, believed to be the most significant data theft event in history. Firms represent a treasure trove of information and historically have had dreadful cybersecurity practices. There has been some progress, but firms can also commit to better defending their information by taking a simple, three-step approach, says Sean D... (continued)

  • In Congress: Defense Bill, TSCA Reform, Authority Over DC

    Richard A. Hertling

    In a busy lead-up to the Memorial Day recess, this week is likely to showcase instances in which Congress has been able to come together and enact important legislation and those in which contentious partisan and ideological divides are on display, say Richard Hertling and Zephanie Custer of Covington & Burling LLP.